
Release date: 2026-01-26 15:26:43 Article From: Lucius Laos Recommended: 13
Lorlatinib is a targeted therapy indicated for the treatment of ALK-positive non-small cell lung cancer (NSCLC). Its dietary restrictions primarily aim to avoid foods that may interfere with drug metabolism, exacerbate side effects, or compromise therapeutic efficacy. While there is no well-defined classification of "top 10 forbidden foods" in clinical medicine, the following key dietary principles should be strictly observed:
Grapefruits, pomelos, and other related fruits may inhibit the activity of CYP3A4 enzymes in the liver. This inhibition can elevate the plasma concentration of lorlatinib, thereby increasing the risk of adverse reactions such as liver injury and cardiac arrhythmias. Consumption of relevant fruit juices or pulp is strongly discouraged throughout the entire course of medication.
High-fat diets can delay drug absorption and undermine the stability of therapeutic effects. During the treatment period, it is advisable to reduce the intake of fried foods, fatty meats, cream cakes, and similar items, and instead opt for light, easily digestible proteins and vegetables.
Alcohol may impose an additional burden on liver metabolism. Concurrent use with lorlatinib could induce or aggravate adverse reactions including liver damage, nausea, and headaches. Strict abstinence from alcohol is mandatory.
Lorlatinib may cause edema or hypertension. High-salt foods such as pickled products, processed meats (e.g., ham, sausages), and sauces can exacerbate these side effects, so their consumption should be limited.
Coffee, strong tea, energy drinks, and other caffeinated products may worsen medication-induced insomnia, palpitations, or gastrointestinal discomfort. It is recommended to control the intake of such beverages.
Herbal products like St. John's Wort, ginseng, and ginkgo biloba may interfere with the activity of drug-metabolizing enzymes, potentially affecting therapeutic efficacy or increasing toxicity. Patients must inform their physicians of any supplements they are taking prior to starting lorlatinib treatment.
High-calcium foods (e.g., milk, cheese) can form chelates with lorlatinib, reducing its absorption rate. It is recommended to avoid consuming large quantities of these foods 2 hours before or after taking the medication.
Patients with compromised immune function should avoid raw fish, soft-boiled eggs, and similar items to minimize the risk of infection.
No absolute dietary prohibitions, but monitor bodily responses: If a particular food triggers significant discomfort (e.g., diarrhea, vomiting), patients should document the occurrence and promptly report it to their treating physician.
Timing interval between medication and meals: Lorlatinib is generally recommended to be taken on an empty stomach (1 hour before or 2 hours after meals). Specific administration instructions must be followed in accordance with the physician’s advice.
Fluid intake: Adequate daily water consumption helps promote metabolism, but excessive intake should be avoided to prevent edema.
The core objective of dietary restrictions for lorlatinib is to minimize drug interactions and reduce the risk of side effects. These restrictions should be adjusted based on individual patient conditions rather than adhering to a rigid, one-size-fits-all list. During the treatment period, patients should undergo regular monitoring of liver function, blood pressure, and other relevant indicators, and maintain close communication with their attending physicians to develop a personalized dietary plan.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended:732025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:3692024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended:652025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended:822025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended:822025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended:982025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended:942025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended:952025-27-11

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: